Profile picture of Fenella Willis

Dr Fenella Willis

Profile picture of Fenella Willis

MBBS, BSc, FRCP, FRCPath, MD

Consultant Haematologist
GMC: 4015570
Call
Icon Cancer Centre London

Biography

Dr Fenella Willis is a Consultant Haematologist at St George’s Hospital, where she has been practicing since 2004. She has also held an Honorary Senior Lecturer position at the St George’s University Medical School since the same year. Dr Willis specialises in Haemato-Oncology and is the clinical lead for both the Myeloma and Apheresis services at St George’s Hospital. Additionally, she serves as the Principal Investigator for a broad portfolio of Myeloma and Haemato-Oncology clinical trials, contributing to cutting-edge research in these fields. 

Dr Willis completed her medical degree at the Royal Free Hospital in London, graduating with distinction in 1993. Following this, she underwent specialist training in Haematology as part of the South West London rotation from 1996 to 2004, during which she obtained her Certificate of Completion of Specialist Training (CCST) in Haematology. During her training, she also completed an MD thesis on “Optimising Peripheral Blood Progenitor Cell Mobilisation,” further advancing her expertise in the field. 

In addition to her clinical and academic roles, Dr Willis is deeply committed to charity work. She is a Trustee for Myeloma UK, a charity dedicated to supporting patients, improving access to treatments, and promoting research in Myeloma. She also serves as a Trustee for the Full Circle Fund Charity, which provides supportive care therapies to adults and children living with life-limiting and chronic diseases. 

Dr Willis is a Fellow of both the Royal College of Physicians and the Royal College of Pathologists. She is an active member of the British Society of Haematology and the UKMS (UK Myeloma Society). Her career reflects a deep commitment to advancing Haemato-Oncology care, educating the next generation of medical professionals, and supporting vital patient and research initiatives. 

Publications

  • Wheeler RD, Costa MV, Crichlow A, Willis F, Reyal Y, Linstead SE, Morris JE Case report: Interference from isatuximab on serum protein electrophoresis prevented demonstration of complete remission in a myeloma patient. .Ann Clin Biochem. 2022 Mar;59(2):144-148 

  • Divekar O, Ajayi B, Barkham B, Bernard J, Bishop T, Reyal Y, Willis F, Boyd K, Lui D, Coomber Chemotherapy May Obviate Prophylactic Femoral Nail Surgery for Multiple Myeloma Patients With High Mirels‘ Score Lesions and Impending Pathological Hip Fracture. Cureus. 2023 Apr 17;15(4) 

  • Porteous A, Gibson S, Eddowes LA, Drayson M, Pratt G, Bowcock S, Willis F, Parkin H, Renwick S, Laketic-Ljubojevic I, Howell D, Smith A, Stern S An Economic Model to Establish the Costs Associated With Routes to Presentation for Patients With Multiple Myeloma in the United Kingdom. Value Health Reg Issues. 2023 May;35:27-33.  

  • May PC, Reid AG, Robinson ME, Khorashad JS, Milojkovic D, Claudiani S; Genomics England Research Consortium; Willis F, Apperley JF, Innes AJ FISH-negative BCR::ABL1-positive e19a2 chronic myeloid leukaemia: the most cryptic of insertions. BMC Med Genomics. 2023 Jul 26;16(1):172.  

  • Stern S, Chaudhuri S, Drayson M, Henshaw S, Karunanithi K, Willis F; Haemato-Oncology Task Force of the British Society for Haematology and the UK Myeloma Forum Investigation and management of the monoclonal gammopathy of undetermined significance: A British Society for Haematology Good Practice Paper. Br J Haematol. 2023 Aug;202(4):734-744.  

Special Interests

Dr Fenella Willis accepts referrals for all cancer types, with a special clinical interest in:

  • Haematology
  • Leukaemia
  • Multiple myeloma
  • Myeloproliferative neoplasms

Languages spoken

  • English

Other Posts Held

  • St George’s University Hospital NHS Foundation Trust 

Affiliations & Memberships

  • Fellow of the Royal College of Physicians
  • Fellow of the Royal College of Pathologists
  • Member of the British Society of Haematology
  • Member of the UK Myeloma Society

Publications

  • Wheeler RD, Costa MV, Crichlow A, Willis F, Reyal Y, Linstead SE, Morris JE Case report: Interference from isatuximab on serum protein electrophoresis prevented demonstration of complete remission in a myeloma patient. .Ann Clin Biochem. 2022 Mar;59(2):144-148 

  • Divekar O, Ajayi B, Barkham B, Bernard J, Bishop T, Reyal Y, Willis F, Boyd K, Lui D, Coomber Chemotherapy May Obviate Prophylactic Femoral Nail Surgery for Multiple Myeloma Patients With High Mirels‘ Score Lesions and Impending Pathological Hip Fracture. Cureus. 2023 Apr 17;15(4) 

  • Porteous A, Gibson S, Eddowes LA, Drayson M, Pratt G, Bowcock S, Willis F, Parkin H, Renwick S, Laketic-Ljubojevic I, Howell D, Smith A, Stern S An Economic Model to Establish the Costs Associated With Routes to Presentation for Patients With Multiple Myeloma in the United Kingdom. Value Health Reg Issues. 2023 May;35:27-33.  

  • May PC, Reid AG, Robinson ME, Khorashad JS, Milojkovic D, Claudiani S; Genomics England Research Consortium; Willis F, Apperley JF, Innes AJ FISH-negative BCR::ABL1-positive e19a2 chronic myeloid leukaemia: the most cryptic of insertions. BMC Med Genomics. 2023 Jul 26;16(1):172.  

  • Stern S, Chaudhuri S, Drayson M, Henshaw S, Karunanithi K, Willis F; Haemato-Oncology Task Force of the British Society for Haematology and the UK Myeloma Forum Investigation and management of the monoclonal gammopathy of undetermined significance: A British Society for Haematology Good Practice Paper. Br J Haematol. 2023 Aug;202(4):734-744.  

Search

Contact us
Contact Us